Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY).
Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY).
复制标题
DOI：
10.1158/1078-0432.ccr-21-0641
复制
发表时间：
2021-09-01
期刊：
影响因子：
--
通讯作者：
Goetz MP
中科院分区：
文献类型：
--
作者：
Boughey JC;Suman VJ;Yu J;Santo K;Sinnwell JP;Carter JM;Kalari KR;Tang X;McLaughlin SA;Moreno-Aspitia A;Northfelt DW;Gray RJ;Hunt KN;Conners AL;Ingle JN;Moyer A;Weinshilboum R;Copland JA 3rd;Wang L;Goetz MP
患者来源的异种移植物(PDX)是研究肿瘤生物学和药物反应表型的研究工具。尽管更具侵袭性的肿瘤的植入率较高，但植入率是否预示癌症复发尚不确定。在一项前瞻性研究中，乳腺癌患者先接受紫杉烷+/−曲妥珠单抗的新辅助化疗，然后再接受以蒽环类药物为基础的化疗，我们报告了乳腺癌事件与使用源自治疗单纯(113名患者的新辅助化疗前活检)和治疗耐药(34名患者手术后新辅助化疗后)肿瘤的PDX植入之间的关系。Gray‘s检验用于评估乳腺癌事件的累积发生率是否与植入NAC PDX前或植入NAC PDX后不同。中位随访期为5.7年，乳腺癌的累积复发率与植入NAC PDX前无显著差异(5年复发率：13.6%对13.4%；p=0.89)。然而，植入NAC后PDX的患者乳房事件的发生率更高(5年发生率：50.0%对19.6%)，但这并不具有统计学意义(p=0.11)。在接受标准NAC治疗的初治乳腺癌患者中，PDX植入并不预示乳腺癌复发的预后。在耐药环境中植入PDX是否预示癌症复发，还需要进一步的研究。
Patient derived xenografts (PDXs) are a research tool for studying cancer biology and drug response phenotypes. While engraftment rates are higher for tumors with more aggressive characteristics, it is uncertain whether engraftment is prognostic for cancer recurrence. In a prospective study of breast cancer patients treated with neoadjuvant chemotherapy (NAC) with taxane+/−trastuzumab followed by anthracycline-based chemotherapy, we report the association between breast cancer events and PDX engraftment using tumors derived from treatment naïve (pre-NAC biopsies from 113 patients) and treatment resistant (post-NAC at surgery from 34 patients). Gray’s test was used to assess whether the cumulative incidence of a breast cancer event differs with respect to either pre-NAC PDX engraftment or post-NAC PDX engraftment. With a median follow up of 5.7 years, the cumulative incidence of breast cancer relapse did not differ significantly according to pre-NAC PDX engraftment (5-year rate: 13.6% versus 13.4%; p=0.89). However, the incidence of a breast event was greater for patients with post-NAC PDX engraftment (5-year rate: 50.0% versus 19.6%), but this did not achieve significance (p=0.11). In treatment-naive breast cancer receiving standard NAC, PDX engraftment was not prognostic for breast cancer recurrence. Further study is needed to establish whether PDX engraftment in the treatment-resistant setting is prognostic for cancer recurrence.